MA49396B1 - Traitement de la migraine avec acétyl-leucine - Google Patents

Traitement de la migraine avec acétyl-leucine

Info

Publication number
MA49396B1
MA49396B1 MA49396A MA49396A MA49396B1 MA 49396 B1 MA49396 B1 MA 49396B1 MA 49396 A MA49396 A MA 49396A MA 49396 A MA49396 A MA 49396A MA 49396 B1 MA49396 B1 MA 49396B1
Authority
MA
Morocco
Prior art keywords
leucine
migraine
acetyl
treatment
subject
Prior art date
Application number
MA49396A
Other languages
English (en)
French (fr)
Other versions
MA49396A (fr
Inventor
Michael Strupp
Mallory Factor
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49396(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA49396A publication Critical patent/MA49396A/fr
Publication of MA49396B1 publication Critical patent/MA49396B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA49396A 2017-06-14 2018-06-25 Traitement de la migraine avec acétyl-leucine MA49396B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine

Publications (2)

Publication Number Publication Date
MA49396A MA49396A (fr) 2020-04-22
MA49396B1 true MA49396B1 (fr) 2021-03-31

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49396A MA49396B1 (fr) 2017-06-14 2018-06-25 Traitement de la migraine avec acétyl-leucine

Country Status (25)

Country Link
US (1) US11471434B2 (https=)
EP (1) EP3638370B1 (https=)
JP (1) JP7130739B2 (https=)
KR (1) KR102594130B1 (https=)
CN (1) CN111093772B (https=)
AU (1) AU2018284330B2 (https=)
CY (1) CY1123860T1 (https=)
DK (1) DK3638370T3 (https=)
ES (1) ES2847169T3 (https=)
GB (1) GB201709459D0 (https=)
HR (1) HRP20210108T1 (https=)
HU (1) HUE053089T2 (https=)
IL (1) IL271211B2 (https=)
LT (1) LT3638370T (https=)
MA (1) MA49396B1 (https=)
MD (1) MD3638370T2 (https=)
MX (1) MX387909B (https=)
PL (1) PL3638370T3 (https=)
PT (1) PT3638370T (https=)
RS (1) RS61481B1 (https=)
SG (1) SG11201912146RA (https=)
SI (1) SI3638370T1 (https=)
SM (1) SMT202100037T1 (https=)
WO (1) WO2018229738A1 (https=)
ZA (1) ZA201908087B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7337081B2 (ja) * 2018-02-15 2023-09-01 イントラバイオ リミティド レストレスレッグズ症候群を治療するための治療薬
JP7471298B2 (ja) * 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル-ロイシンの重水素化類似体

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
SI1641775T1 (sl) * 2003-07-03 2009-08-31 Euro Celtique Sa 2-piridin alkinski derivati, uporabni za zdravljenje bolečine
SI1867644T1 (sl) * 2003-07-24 2009-10-31 Euro Celtique Sa Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine
EP1664041B1 (en) * 2003-09-22 2008-07-02 Euro-Celtique S.A. Phenyl-carboxamide compounds useful for treating pain
PL1664016T3 (pl) * 2003-09-22 2009-04-30 Euro Celtique Sa Środki terapeutyczne przydatne do leczenia bólu
ES2322907T3 (es) * 2003-12-30 2009-07-01 Euro-Celtique S.A. Piperazinas utiles para el tratamiento de dolor.
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2011162409A1 (en) * 2010-06-22 2011-12-29 Shionogi & Co., Ltd. Compounds having trpv1 antagonistic activity and uses thereof
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
MX340112B (es) * 2010-11-09 2016-06-27 Mannkind Corp Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
US9394293B2 (en) * 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US10905670B2 (en) 2016-04-19 2021-02-02 Intrabio Ltd. Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
NZ750391A (en) 2016-08-11 2026-03-27 Intrabio Ltd Pharmaceutical compositions and uses directed to lysosomal storage disorders
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
FI3600276T3 (fi) 2017-03-28 2023-06-29 Intrabio Ltd Betahistiini tai sen farmaseuttisesti hyväksyttävä suola ja monoamiinioksidaasin inhibiittori käytettäväksi yhden tai useamman huimausoireen hoitamisessa tai ehkäisemisessä kohteessa
LT3697399T (lt) 2017-10-18 2026-01-12 Intrabio Ltd Terapiniai agentai, skirti panaudoti gydant neramių kojų sindromą
US12458614B2 (en) 2017-10-18 2025-11-04 Intrabio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
JP7337081B2 (ja) 2018-02-15 2023-09-01 イントラバイオ リミティド レストレスレッグズ症候群を治療するための治療薬
JP7471298B2 (ja) 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル-ロイシンの重水素化類似体
WO2020178721A1 (en) 2019-03-02 2020-09-10 Intrabio Ltd. Leucine, acetyl leucine, and related analogs for treating disease
SI3989962T1 (sl) 2019-06-28 2025-11-28 Intrabio Ltd Kombinirano zdravljenje z acetil-levcinom in miglustatom za zdravljenje lizosomske bolezni kopičenja
US20230051742A1 (en) 2020-01-13 2023-02-16 Intrabio Ltd. Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Also Published As

Publication number Publication date
CY1123860T1 (el) 2022-05-27
HUE053089T2 (hu) 2021-06-28
WO2018229738A1 (en) 2018-12-20
GB201709459D0 (en) 2017-07-26
RU2020100475A (ru) 2021-07-14
RS61481B1 (sr) 2021-03-31
CN111093772A (zh) 2020-05-01
JP7130739B2 (ja) 2022-09-05
ZA201908087B (en) 2024-11-27
PL3638370T3 (pl) 2021-05-17
RU2020100475A3 (https=) 2021-10-22
KR20210013518A (ko) 2021-02-04
AU2018284330B2 (en) 2024-03-14
SI3638370T1 (sl) 2021-04-30
CN111093772B (zh) 2023-11-03
ES2847169T3 (es) 2021-08-02
EP3638370A1 (en) 2020-04-22
HRP20210108T1 (hr) 2021-03-19
US11471434B2 (en) 2022-10-18
MA49396A (fr) 2020-04-22
IL271211B1 (en) 2023-09-01
MX2019014784A (es) 2021-11-16
DK3638370T3 (da) 2021-01-25
AU2018284330A1 (en) 2020-01-02
MD3638370T2 (ro) 2021-04-30
IL271211A (en) 2020-01-30
LT3638370T (lt) 2021-03-25
CA3067321A1 (en) 2018-12-20
EP3638370B1 (en) 2020-11-11
PT3638370T (pt) 2021-01-26
JP2020526575A (ja) 2020-08-31
US20200253905A1 (en) 2020-08-13
IL271211B2 (en) 2024-01-01
KR102594130B1 (ko) 2023-10-24
BR112019026660A2 (pt) 2020-07-14
MX387909B (es) 2025-03-19
SG11201912146RA (en) 2020-01-30
SMT202100037T1 (it) 2021-03-15

Similar Documents

Publication Publication Date Title
MA52219B1 (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
MA43468B1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MA35156B1 (fr) 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoléin-2-one destinée à être utilisée dans le traitement du carcinome adénoïde kystique
MA44612B1 (fr) Méthodes de traitement de cancers pédiatriques
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
MA55199B1 (fr) (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques
FR3032883B1 (fr) Composition pour la prevention et le traitement de la steatose et de la steatohepatite metaboliques
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA49396B1 (fr) Traitement de la migraine avec acétyl-leucine
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
MA54511B1 (fr) Composition ophtalmique nutraceutique pour le traitement de pathologies retiniennes a composante neovasculaire
MA46778B1 (fr) Composition intranasale comprenant de la bétahistine
TN2010000108A1 (fr) Traitement de symtomes vasomoteurs
MA50383B1 (fr) Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos
FR3047665B1 (fr) Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
MA33090B1 (fr) Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au fer
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
MA44769B1 (fr) Formulations destinées à une utilisation dans le traitement ou la prévention de maladies urologiques